GV20 Oncotherapy was started by an expert team trained at world-renowned universities. We are devoted to precision medicine development in cancer immuno-oncology. GV20 Oncotherapy has innovative antibody drug discovery and development platforms that integrate cancer genomics, immuno-oncology, and artificial intelligence. We are utilizing our technological advantages to search novel immunotherapy targets, screen fully human anti-tumor antibodies, and identify robust clinical biomarkers.
Novel Immuno-Oncology Targets
Tumor-Specific Fully Human Antibodies
Robust Response Biomarkers